Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes.
Sharma. Geetanjali G; Hu. Chelin C; Staquicini. Daniela I DI; Brigman. Jonathan...
Adipotide
Prohibitin-targeting peptide 1, Prohibitin-TP01, FTPP
A peptidomimetic that targets prohibitin in white adipose tissue vasculature, inducing apoptosis and leading to rapid weight loss and improved insulin sensitivity.
Molecular Profile
Formula
C111H204N36O28S2
Mol. Weight
2555.22 g/mol
Sequence
Gly-Glu-Pro-Pro...
| Route | |
|---|---|
|
Subcutaneous (SC)
0.43 mg/kg
|
|
|
Oral
Not established
|
How It Works
How It Works: Adipotide is a chimeric peptidomimetic that selectively binds to prohibitin on the surface of blood vessels in white adipose tissue, triggering apoptosis and reducing fat mass.
- Specific binding to prohibitin/annexin A2 receptor complex in white fat vasculature.
- Internalization and disruption of mitochondrial integrity via the D(KLAKLAK)2 domain.
- Induction of endothelial cell apoptosis, leading to ischemia and resorption of adipocytes.
- Improvement in insulin sensitivity and alteration in eating behavior through fat loss.
Latest Clinical Trials
See All Clinical Trials
Terminated
PHASE1
NCT01262664
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
M.D. Anderson Cancer Center
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE2
NCT02252783
BFPET for Regional Myocardial Perfusion Imaging
Fluoropharma, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Latest Studies
See All StudiesEpigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease.
Huang. Rae-Chi RC; Lillycrop. Karen A KA; Beilin. Lawrence J LJ; Godfrey. Keith...
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Preiss. David D; Dawed. Adem A; Welsh. Paul P; Heggie. Alison A; Jones. Angus G...
Taking metformin regularly raises your fasting GLP-1 hormone levels and keeps them higher for at least a year and a half, even if you don’t lose weight or change your blood sugar. This effect shows up in people without diabetes and also in newly diagnosed diabetics, and it’s not just a short‑term spike after a meal.